Establishment Labs (NASDAQ:ESTA) Downgraded by Wall Street Zen to “Hold”

Establishment Labs (NASDAQ:ESTA) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research firms have also recently commented on ESTA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Needham & Company LLC increased their price target on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Canaccord Genuity Group raised their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. JPMorgan Chase & Co. lifted their price objective on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, Stephens upped their target price on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Establishment Labs has an average rating of “Moderate Buy” and an average price target of $86.86.

Establishment Labs Price Performance

NASDAQ:ESTA opened at $55.31 on Friday. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -31.79 and a beta of 0.91. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51. The company’s 50-day moving average is $68.98 and its two-hundred day moving average is $61.88. Establishment Labs has a 12-month low of $26.56 and a 12-month high of $83.31.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The company’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.19) earnings per share. Research analysts expect that Establishment Labs will post -2.41 EPS for the current year.

Insider Buying and Selling

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 33,925 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75. Following the transaction, the director owned 1,223,579 shares of the company’s stock, valued at $73,891,935.81. This trade represents a 2.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 11.09% of the company’s stock.

Institutional Trading of Establishment Labs

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its position in shares of Establishment Labs by 117.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after buying an additional 438,206 shares during the period. Viking Global Investors LP purchased a new stake in Establishment Labs during the second quarter valued at about $14,669,000. Bamco Inc. NY increased its stake in Establishment Labs by 30.2% during the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after acquiring an additional 274,287 shares during the last quarter. Woodson Capital Management LP increased its stake in Establishment Labs by 113.3% during the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after acquiring an additional 255,000 shares during the last quarter. Finally, Soleus Capital Management L.P. purchased a new position in shares of Establishment Labs in the 2nd quarter worth about $9,050,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.